The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the
treatment of hyperlipidemia, and in the long-term prevention of coronary artery disease and
stroke. They have also demonstrated a benefit in a variety of other cardiovascular disease
processes. These secondary actions are known as pleiotropic effects. An updated
discussion on the pleiotropy of statins is provided, and emphasizes the importance of
randomized, placebo-controlled trials to further elucidate the potential benefits of these non …